世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の網膜静脈閉塞症治療市場 2019-2023年

Global Retinal Vein Occlusion Treatment Market 2019-2023

IRTNTR30039

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
106

サマリー

この調査レポートは世界の網膜静脈閉塞症治療市場 を分析・予測したTechNavioの市場調査報告書です。

Description

About Retinal Vein Occlusion
Retinal vein occlusion (RVO) is the buildup of blood or other fluids in the retina of the eye, which prevents it from properly filtering the light caused by the blood clot.
Technavio’s analysts forecast the Global Retinal Vein Occlusion Market to grow at a CAGR of 9.40% during the period 2019-2023.

Covered in this report
The report covers the present scenario and the growth prospects of the retinal vein occlusion treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of retinal vein occlusion across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, retinal vein occlusion treatment market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Allergan
- Bayer
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
Market driver
- Strong pipeline and recent drug approvals
- For a full, detailed list, view our report

Market challenge
- Side effects of RVO therapeutics
- For a full, detailed list, view our report

Market trend
- Advanced drug delivery techniques
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- BRVO - Market size and forecast 2018-2023
- CRVO - Market size and forecast 2018-2023
- Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- ALLERGAN
- Bayer
- F. Hoffmann-La Roche
- Novartis
- Regeneron Pharmaceuticals
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global retinal disorders therapeutics market
Exhibit 02: Segments of global retinal disorders therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: BRVO - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: BRVO - Year-over-year growth 2019-2023 (%)
Exhibit 21: CRVO - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: CRVO - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Increasing geriatric population in APAC
Exhibit 36: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: ALLERGAN - Vendor overview
Exhibit 46: ALLERGAN - Business segments
Exhibit 47: ALLERGAN - Organizational developments
Exhibit 48: ALLERGAN - Segment focus
Exhibit 49: ALLERGAN - Geographic focus
Exhibit 50: ALLERGAN - Segment focus
Exhibit 51: Bayer - Vendor overview
Exhibit 52: Bayer - Business segments
Exhibit 53: Bayer - Organizational developments
Exhibit 54: Bayer - Segment focus
Exhibit 55: Bayer - Geographic focus
Exhibit 56: F. Hoffmann-La Roche - Overview
Exhibit 57: F. Hoffmann-La Roche - Business segments
Exhibit 58: F. Hoffmann-La Roche - Organizational developments
Exhibit 59: F. Hoffmann-La Roche - Geographic focus
Exhibit 60: F. Hoffmann-La Roche - Segment focus
Exhibit 61: Novartis - Vendor overview
Exhibit 62: Novartis - Business segments
Exhibit 63: Novartis - Organizational developments
Exhibit 64: Novartis - Geographic focus
Exhibit 65: Novartis - Segment focus
Exhibit 66: Regeneron Pharmaceuticals - Vendor overview
Exhibit 67: Regeneron Pharmaceuticals - Business segments
Exhibit 68: Regeneron Pharmaceuticals - Organizational developments
Exhibit 69: Regeneron Pharmaceuticals - Segment focus
Exhibit 70: Regeneron Pharmaceuticals - Key customers










 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る